Ro 28-1675
CAS No. 300353-13-3
Ro 28-1675( Ro 028-1675 | RO 0281675 )
Catalog No. M13928 CAS No. 300353-13-3
A potent, allosteric activator of Glucokinase (GK) with SC1.5 of 0.24 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 193 | Get Quote |
|
| 50MG | 849 | Get Quote |
|
| 100MG | 1278 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRo 28-1675
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, allosteric activator of Glucokinase (GK) with SC1.5 of 0.24 uM.
-
DescriptionA potent, allosteric activator of Glucokinase (GK) with SC1.5 of 0.24 uM; augments both hepatic glucose metabolism and glucose-induced insulin secretion from isolated rodent pancreatic islets; lowers blood glucose levels and increases hepatic glucose uptake in rodent models of type 2 diabetes mellitus. Diabetes Preclinical.
-
In VitroRO-28-1675 can reverse the inhibitory action of the human glucokinase regulatory protein (GKRP).
-
In VivoRO-28-1675 (50 mg/kg; p.o.) reduces blood glucose levels in wild-type C57BL/6J mice.RO-28-1675 exhibits high oral bioavailability (mice 92.8%) and Cmax (1140 μg/mL) following oral administration (10 mg/kg). Animal Model:10 weeks old male C57BL/6J mice Dosage:50 mg/kg Administration:Oral administration Result:Reduced blood glucose levels.Animal Model:C57BL/6J mice Dosage:10 mg/kg (Pharmacokinetic Analysis Administration:Oral administration Result:Oral bioavailability (92.8%), Cmax (1140 μg/mL), T max (3.3 h).
-
SynonymsRo 028-1675 | RO 0281675
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetGlucokinase
-
RecptorGlucokinase
-
Research AreaMetabolic Disease
-
IndicationDiabetes
Chemical Information
-
CAS Number300353-13-3
-
Formula Weight378.5089
-
Molecular FormulaC18H22N2O3S2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NC1=NC=CS1)[C@@H](C2=CC=C(S(=O)(C)=O)C=C2)CC3CCCC3
-
Chemical NameBenzeneacetamide, α-(cyclopentylmethyl)-4-(methylsulfonyl)-N-2-thiazolyl-, (αR)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Grimsby J, et al. Science. 2003 Jul 18;301(5631):370-3.
2. Haynes NE, et al. J Med Chem. 2010 May 13;53(9):3618-25.
3. McKerrecher D, Bioorg Med Chem Lett. 2005 Apr 15;15(8):2103-6.et al.
4. Assefa Z, et al. PLoS One. 2014 Jan 9;9(1):e85174.
molnova catalog
related products
-
POMHEX
Pomhex, a cell-permeable potent enolase inhibitor with anticancer activity, is used in the study of cancer lethality.Pomhex, a racemic mixture, is a potent and selective ENO2 inhibitor.
-
Allylglucosinolate m...
Sinigrin exerts important anti-proliferative activities in carcinogen-induced hepatocarcinogenesis in rats, and highlight the potential of Sinigrin as an anti-cancer agent for liver cancer.
-
WAY-297848
WAY-297848 is a novel glucokinase activator for the prevention or treatment of hyperglycemia, diabetes mellitus, obesity, dyslipidemia, and metabolic syndrome.
Cart
sales@molnova.com